<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83425">
  <stage>Registered</stage>
  <submitdate>4/12/2008</submitdate>
  <approvaldate>18/05/2009</approvaldate>
  <actrnumber>ACTRN12609000289213</actrnumber>
  <trial_identification>
    <studytitle>Ocular measures for detection of driving impairment due to sleep loss, alcohol and benzodiazepine use</studytitle>
    <scientifictitle>Ocular measures for detection of driving impairment due to sleep loss, alcohol and benzodiazepine use</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>sleep- and drug-related motor vehicle accident risk</healthcondition>
    <healthcondition>healthy volunteers</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Health promotion/education</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All participants will undergo three randomised sessions, seperated by a 1 week washout period. 1. Sleep restriction session: sleep will be restricted to 4 hours on the night prior to testing (2am to 6am).
2. benzodiazepine session: a single, 20mg oral dose of benzodiazepine administered at 9am, 2 hours prior to testing
3. alcohol session: measured doses of vodka in orange juice will be administrered orally until a blood alcohol concentration (BAC) of 0.05% and 0.08% is reached (checked by alcometer). Testing will commence immediately at each alcohol level. 
During testing, driving simulation and a reaction time task will be completed, while ocular parameters are measured, using optalert and electrooculography (EOG).</interventions>
    <comparator>Alll participants will also complete baseline testing durng each session: 
Sleep restriction session: testing after a normal night of sleep 
benzodiazepine session: testing following a single acute oral dose of 20mg placebo (lactose)
alcohol session: testing at baseline, prior to alcohol administration (BAC = 0.00%)</comparator>
    <control>Placebo</control>
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>ocular measures tested by Optalert: slow eyelid closure, blink amplitude, saccades, EOG</outcome>
      <timepoint>baseline, following intervention during each session</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>driving performance using the AusEd driving simulator: lane position variability</outcome>
      <timepoint>baseline, following intervention in each session</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>healthy, drivers licence, alcohol intake in standard drinks &gt;0 average &lt;5/day for males and &lt; 3/day for females</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1.	Epilepsy
2.	Diabetes requiring insulin
3.	Chronic psychiatric illness
4.	Visual impairment which does not correct with glasses
5.	Unable to speak and read English
6.	Drink more than 5 caffeinated beverages per day
7.	Significant daytime sleepiness (Epworth Sleepiness Scale score &gt; 11). 
8.	Chronic neurological illness
9.	Chronic liver disease, diabetes requiring insulin or renal impairment
10.	Pregnancy or breast feeding
11.	Sleep apnoea, narcolepsy
12.	Use of sedating medication
13.	Anticoagulation with warfarin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Potential particpants will undergo a medical examination, and those who meet the inclusion criteria will be given a randomisation number. Each participant will complete each of the three sessions; the randomisation number indicates the order in which the sessions will be completed.</concealment>
    <sequence>The randomisation sequence is created by the pharmacy at Austin Health.The sequence will be generated using a simple computerised sequence randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/03/2008</anticipatedstartdate>
    <actualstartdate>1/04/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>6/12/2010</actualenddate>
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress>Studley Rd, Heidelberg, Victoria 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Institute for Breathing &amp; Sleep</fundingname>
      <fundingaddress>Studley Rd, Heidelberg, Victoria 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will examine whether the impairing effects of sleep loss, alcohol and hypnotic drugs can be detected using a simulated driving task and drowsiness monitoring technology in the laboratory setting. The hypothesis of this study is that performance deterioration, as a result of sleep restriction and acute benzodiazepine administration, can be detected by increases in slow eyelid closure, a reduction in amplitude of eyelid opening and a reduction in saccadic eye movements, as measured by Optalert.</summary>
    <trialwebsite />
    <publication>Wilkinson VE, Jackson ML, Barnes M, Stevens B, Westlake J, Stevens B, Swann P, Rajaratnam S, Howard ME. (in press).The accuracy of eyelid movement parameters for detecting behavioral lapses following sleep restriction. Journal of Clinical Sleep Medicine. Accepted 14th September, 2013.

Wilkinson VE, Jackson ML, Barnes M, Stevens B, Westlake J, Swann P, Howard ME. (2012). Perception of driving ability is impaired by sleep enhancing medication. Sleep &amp; Biological Rhythms, 10 (Supp 1): 6.

Howard ME, Wilkinson VE, Jackson ML, Barnes M, Stevens B, Westlake J, Swann P, Rajaratnam SW. (2012). The accuracy of eyelid movement parameters for detecting lapses following sleep restriction. Sleep, 35: A108.

Wilkinson VE, Jackson ML, Barnes M, Stevens B, Westlake J, Swann P, Howard ME. (2012). Changes in ocular measures due to benzodiazepines and alcohol consumption. Occupational Safety in Transport (OSIT) Conference.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health Human Ethics Comittee</ethicname>
      <ethicaddress>Research Ethics Unit
Level 8 HSB Room 8322
Austin Health
Heidelberg, Victoria 3084</ethicaddress>
      <ethicapprovaldate>26/10/2010</ethicapprovaldate>
      <hrec>3435</hrec>
      <ethicsubmitdate>5/12/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Bronwyn Stevens</name>
      <address>Institute for Breathing &amp; Sleep
Studley Rd, Heidelberg, Victoria 3084</address>
      <phone>+613 9496 3528</phone>
      <fax />
      <email>bronwyn.stevens@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Melinda Jackson</name>
      <address>Institute for Breathing &amp; Sleep
Studley Rd, Heidelberg, Victoria 3084</address>
      <phone>+613 9496 3528</phone>
      <fax />
      <email>melinda.jackson@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mark Howard</name>
      <address>Institute for Breathing and Sleep, Austin Health
Heidelberg, Victoria, 3084</address>
      <phone>+613 9496 3877</phone>
      <fax />
      <email>mark.howard@austin.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>